Kilitch Drugs(India) Stock Price Analysis and Quick Research Report. Is Kilitch Drugs(India) an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Kilitch Drugs(India). 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Kilitch Drugs(India) has a PE ratio of 19.7339574244185 which is high and comparatively overvalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Kilitch Drugs(India) has ROA of 6.5653% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Kilitch Drugs(India) has a Current ratio of 2.1979.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Kilitch Drugs(India) has a ROE of 8.5073%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Kilitch Drugs(India) has a Debt to Equity ratio of 0.1407 which means that the company has low proportion of debt in its capital.

• Sales growth: Kilitch Drugs(India) has reported revenue growth of 11.7296% which is poor in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Kilitch Drugs(India) for the current financial year is 15.5197227942461%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Kilitch Drugs(India) is Rs 0 and the yield is 0%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Kilitch Drugs(India) is Rs 18.2452. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Kilitch Drugs(India) in Ticker for free. Also, one can get the intrinsic value of Kilitch Drugs(India) by using Valuation Calculators, which are available with a Finology ONE subscription. 

Kilitch Drugs(India) FAQs

Q1. What is Kilitch Drugs(India) share price today?
Ans: The current share price of Kilitch Drugs(India) is Rs 360.05.

Q2. What is the market capitalisation of Kilitch Drugs(India)?
Ans: Kilitch Drugs(India) has a market capitalisation of Rs 629.39555591 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Kilitch Drugs(India)?
Ans: The PE ratio of Kilitch Drugs(India) is 19.7339574244185 and the P/B ratio of Kilitch Drugs(India) is 2.04574096106927, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Kilitch Drugs(India) share?
Ans: The 52-week high share price of Kilitch Drugs(India) is Rs 500, and the 52-week low share price of Kilitch Drugs(India) is Rs 293.526455384615.

Q5. Does Kilitch Drugs(India) pay dividends?
Ans: Currently, Kilitch Drugs(India) does not pay dividends. Dividend yield of Kilitch Drugs(India) is around 0%.

Q6. What are the face value and book value of Kilitch Drugs(India) shares?
Ans: The face value of Kilitch Drugs(India) shares is Rs 10, while the book value per share of Kilitch Drugs(India) is around Rs 175.9998. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Kilitch Drugs(India)?
Ans: Kilitch Drugs(India) has a total debt of Rs 31.3171 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Kilitch Drugs(India)?
Ans: The ROE of Kilitch Drugs(India) is 8.5073% and ROCE of Kilitch Drugs(India) is 10.7484%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Kilitch Drugs(India) a good buy for the long term?
Ans: The Kilitch Drugs(India) long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Kilitch Drugs(India) undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Kilitch Drugs(India) appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Kilitch Drugs(India)’s financials?
Ans: You can review Kilitch Drugs(India)’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.